Alexion valuation could choke any Roche bid

ZURICH (Reuters) – Buying Alexion Pharmaceuticals Inc would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drug maker is ultimately not willing to pay.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.